Zobrazeno 1 - 10
of 1 726
pro vyhledávání: ''
Autor:
Aleksandra Sobiborowicz, Dominika Nowis, Paweł Jabłoński, Agnieszka Borowiec, Anna A Marusiak, Alicja Mazan, Monika K. Prelowska, Dawid Mehlich, Adam Gorczyński, Ewa Iżycka-Świeszewska, Michał Łomiak, Łukasz M. Szewczyk, Dagmara Dymerska, Anna Mehlich
Publikováno v:
Cell Death and Disease, Vol 12, Iss 12, Pp 1-13 (2021)
Cell Death & Disease
Cell Death & Disease
Chemoresistance constitutes a major challenge in the treatment of triple-negative breast cancer (TNBC). Mixed-Lineage Kinase 4 (MLK4) is frequently amplified or overexpressed in TNBC where it facilitates the aggressive growth and migratory potential
Autor:
Zhigang Tian, Xiaokun Shen, Rui Sun, Chuang Guo, Binqing Fu, Haiming Wei, Jiabin Li, Dongyao Wang, Ying Ye, Junfei Zhang, Yanyan Liu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-13 (2021)
Signal Transduction and Targeted Therapy
Signal Transduction and Targeted Therapy
Patients with chronic hepatitis B (CHB) undergoing interferon (IFN)-α-based therapies often exhibit a poor HBeAg serological response. Thus, there is an unmet need for new therapies aimed at CHB. This study comprised two clinical trials, including 1
Autor:
Sara Hultberg, Kurt Wahlstedt, Margareta Reis, Jörgen Rosén, Kristoffer N.T. Månsson, Olof R. Hjorth, Malin Gingnell, Vanda Faria, Andreas Frick, Johanna M. Hoppe, Mark Lubberink, Mats Fredrikson, Iman Alaie, Tomas Furmark, Gunnar Antoni, My Jonasson
Publikováno v:
Translational Psychiatry, Vol 11, Iss 1, Pp 1-8 (2021)
Translational Psychiatry
Translational Psychiatry
It has been extensively debated whether selective serotonin reuptake inhibitors (SSRIs) are more efficacious than placebo in affective disorders, and it is not fully understood how SSRIs exert their beneficial effects. Along with serotonin transporte
Autor:
Eli Muchtar, Prashant Kapoor, Lisa Hwa, David Dingli, Taxiarchis Kourelis, Amie Fonder, Morie A. Gertz, Matthew Ho, Shaji Kumar, Suzanne R. Hayman, Saurabh Zanwar, Francis K. Baudi, Nelson Leung, Robert A. Kyle, Miriam Hobbs, Martha Q. Lacy, Angela Dispenzieri, Rahma Warsame, S. Vincent Rajkumar
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-10 (2021)
Blood Cancer Journal
Blood Cancer Journal
The optimal duration of lenalidomide maintenance post-autologous stem cell transplant (ASCT) in Multiple Myeloma (MM), and choice of therapy at relapse post-maintenance, need further evaluation. This retrospective study assessed outcomes of patients
Autor:
Betsy LaPlant, Thomas M. Habermann, Ivana N. Micallef, Luis F. Porrata, Rebecca L. King, Yucai Wang, Stephen M. Ansell, William R. Macon, Patrick B. Johnston, David J. Inwards, Thomas E. Witzig, Sanjal Desai, Grzegorz S. Nowakowski
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-7 (2021)
Blood Cancer Journal
Blood Cancer Journal
Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of
Publikováno v:
Cell Death and Disease, Vol 12, Iss 8, Pp 1-12 (2021)
Cell Death & Disease
Cell Death & Disease
Conventional chemotherapy is still of great utility in oncology and rationally constructing combinations with it remains a top priority. Drug-induced mitochondrial apoptotic priming, measured by dynamic BH3 profiling (DBP), has been shown in multiple
Autor:
Yucai Wang, Arushi Khurana, Thomas M. Habermann, Jose C. Villasboas, Brian K. Link, William R. Macon, Stephen M. Ansell, Matthew J. Maurer, Raphael Mwangi, James R. Cerhan, Rebecca L. King, Christopher Strouse, Grzegorz S. Nowakowski, Thomas E. Witzig
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 7, Pp 1-6 (2021)
Blood Cancer Journal
Blood Cancer Journal
Immediate treatment for asymptomatic, low-tumor burden follicular lymphoma (FL) has not shown an overall survival benefit over “watch and wait” (W/W) strategy. We estimated incidence of treatment initiation at specific time points and assessed it
Publikováno v:
Cell Death and Disease, Vol 12, Iss 8, Pp 1-10 (2021)
Cell Death & Disease
Cell Death & Disease
Chemotherapy remains the primary treatment of advanced solid cancer, including lung cancer. However, as first-line treatment, cisplatin-based therapy is restricted by the frequent development of drug resistance. Increasing data showed that the progra
Autor:
Jiarui Liu, Shuai Ren, Yang Han, Xin Wang, Xiangxiang Zhou, Shunfeng Hu, Juan Yang, Yi Zhao, Yiqing Cai
Publikováno v:
Cell Death and Disease, Vol 12, Iss 7, Pp 1-10 (2021)
Cell Death & Disease
Cell Death & Disease
Polo-like kinase 4 (PLK4), a key regulator of centriole biogenesis, has recently been shown to play key roles in tumorigenesis. Blocking PLK4 expression by interference or targeted drugs exhibits attractive potential in improving the efficacy of chem
Autor:
Changrui Qian, Yaqi Wang, Kaiyan Yang, Tianhao Ren, Hongzhi Li, Jiawei Cao, Yingshuai Lv, Haihua Gu, Jieyi Wang, Yang Wang, Du Wu, Guang Wu, Licai He, Wei Sun
Publikováno v:
Cell Death and Disease, Vol 12, Iss 6, Pp 1-13 (2021)
Cell Death & Disease
Cell Death & Disease
Although endocrine therapies targeting estrogen receptor α (ERα) are effective in managing ER positive (+) breast cancer, many patients have primary resistance or develop resistance to endocrine therapies. In addition, ER+ breast cancer with PIK3CA